Tool: A Clinical-Trial Start-Up Dossier for a Foreign Drug Sponsor in China — the NMPA IND Filing, the Ethics Committee Approval and the Human Genetic Resources Filing Behind Every Sample Export

Date:

Share post:

Information date: 13 November 2026 — A foreign drug sponsor running a trial in China needs three parallel approvals, not one: an investigational new drug (IND) acceptance from NMPA’s Center for Drug Evaluation, ethics committee approval at each participating site, and — whenever human samples or data leave the country — a human genetic resources (HGR) filing or approval with the Ministry of Science and Technology. The IND review clock is 60 working days, during which CDE may issue a question letter that stops the clock until answered. If the trial is China-only, file IND first and let ethics follow, because the CDE letter is the gate. If the trial feeds a global registration, build the HGR filing into the protocol timeline from the outset and contract a licensed CRO before site selection. If the sponsor intends to export data rather than samples, confirm whether the same filing covers it — the rules treat data export separately in several cases.

Verified facts and scope

A foreign drug sponsor running a trial in China needs three parallel approvals, not one: an investigational new drug (IND) acceptance from NMPA’s Center for Drug Evaluation, ethics committee approval at each participating site, and — whenever human samples or data leave the country — a human genetic resources (HGR) filing or approval with the Ministry of Science and Technology. The IND review clock is 60 working days, during which CDE may issue a question letter that stops the clock until answered.

Scope has to be fixed before the numbers mean anything: Covers Phase I–III trials of chemical and biological drugs sponsored by a non-Chinese entity, whether conducted directly or through a Chinese affiliate. Pre-check: whether the drug is already approved in a reference market, whether the CRO holds the HGR administrative licence needed to export samples, whether the site’s ethics committee is registered, and whether any trial data will be used for a simultaneous global filing. Anything outside that set is a separate question with its own evidence requirement, and mixing the two is the most common way a workable plan turns into an unusable one.

For a decision on “Tool: A Clinical-Trial Start-Up Dossier for a Foreign Drug Sponsor in China — the NMPA IND Filing, the Ethics Committee Approval and the Human Genetic Resources Filing Behind Every Sample Export”, keep three layers apart: the published rule or statistic, the company’s own orders and process records, and the assumptions nobody has tested yet. The first layer defines the external conditions, the second proves what is true for this business, and the third is where the risk actually sits. Public material cannot substitute for a contract, a system log, a sample or a live test.

A practical way to test the scope is to ask which parts of “Tool: A Clinical-Trial Start-Up Dossier for a Foreign Drug Sponsor in China — the NMPA IND Filing, the Ethics Committee Approval and the Human Genetic Resources Filing Behind Every Sample Export” would still be true if the company changed supplier, entity or product line tomorrow. Items that survive that change belong to the rule layer and can be taken from official publications; items that do not survive belong to the operating layer and have to be rebuilt from invoices, warehouse records, customs entries or platform statements. Where Covers Phase I–III trials of chemical and biological drugs sponsored by a non-Chinese entity, whether conducted directly or through a Chinese affiliate. Pre-check: whether the drug is already approved in a reference market, whether the CRO holds the HGR administrative licence needed to export samples, whether the site’s ethics committee is registered, and whether any trial data will be used for a simultaneous global filing, the two layers are frequently mistaken for each other, and an action plan built on the wrong one either over-complies or misses a deadline it never saw coming.

How the effect reaches operations

The HGR regime exists because human genetic material is treated as a national resource rather than ordinary cargo. That is why the sponsor’s CRO, not the sponsor, usually needs the export licence, and why the filing must precede the first shipment rather than accompany it. The ethics approval is sequenced after IND acceptance in practice because committees want to see the CDE acceptance letter before reviewing the protocol.

Sponsors commonly budget for the IND clock and forget the HGR review, which can run weeks longer and sits on the critical path for any biomarker or pharmacokinetic sampling. A second frequent error is assuming a foreign-language protocol can be submitted with a courtesy translation — sites require a signed Chinese version. Exporting samples under a research-collaboration filing when the actual arrangement is a commercial one is a compliance failure, not a paperwork gap.

Translated into an operating sequence, The HGR regime exists because human genetic material is treated as a national resource rather than ordinary cargo. That is why the sponsor’s CRO, not the sponsor, usually needs the export licence, and why the filing must precede the first shipment rather than accompany it. The ethics approval is sequenced after IND acceptance in practice because committees want to see the CDE acceptance letter before reviewing the protocol. That ordering matters: check applicability first, then the transmission step, and only then the size of the gap in cost or timing. When an intermediate step cannot be confirmed, the honest response is to narrow the scope of the conclusion rather than to substitute an industry average for the company’s own figures.

The cost of getting the order wrong is asymmetric. A team that checks applicability too late usually discovers it at the point where the shipment, the filing or the invoice can no longer be changed without penalty, and by then the only remaining lever is price. A team that checks early spends a few hours on questions that turn out to be irrelevant, which is cheap by comparison. On “Tool: A Clinical-Trial Start-Up Dossier for a Foreign Drug Sponsor in China — the NMPA IND Filing, the Ethics Committee Approval and the Human Genetic Resources Filing Behind Every Sample Export” the practical rule is therefore to spend the first hour on scope and the second on the numbers, never the other way round.

Decision

If the trial is China-only, file IND first and let ethics follow, because the CDE letter is the gate. If the trial feeds a global registration, build the HGR filing into the protocol timeline from the outset and contract a licensed CRO before site selection. If the sponsor intends to export data rather than samples, confirm whether the same filing covers it — the rules treat data export separately in several cases.

The conditions should be written down so the decision can be re-run by someone else: Covers Phase I–III trials of chemical and biological drugs sponsored by a non-Chinese entity, whether conducted directly or through a Chinese affiliate. Pre-check: whether the drug is already approved in a reference market, whether the CRO holds the HGR administrative licence needed to export samples, whether the site’s ethics committee is registered, and whether any trial data will be used for a simultaneous global filing. When those hold, proceed as described; when one is missing, close the gap first and decide afterwards. General orientation for foreign sponsors, not regulatory or legal advice. NMPA and MOST practice changes; verify current requirements with CDE and the human genetic resources office before submission.

Two workstreams usually have to move in parallel. The compliance workstream closes the document side of “Tool: A Clinical-Trial Start-Up Dossier for a Foreign Drug Sponsor in China — the NMPA IND Filing, the Ethics Committee Approval and the Human Genetic Resources Filing Behind Every Sample Export” — registrations, confirmations, filings — while the commercial workstream protects the delivery date, the pricing already quoted and the customer commitments that were made on the earlier reading of the rules. Running them as one queue is how small documentation gaps become missed shipment dates: the commercial side waits for a certificate that could have been requested a week earlier. If the trial is China-only, file IND first and let ethics follow, because the CDE letter is the gate. If the trial feeds a global registration, build the HGR filing into the protocol timeline from the outset and contract a licensed CRO before site selection. If the sponsor intends to export data rather than samples, confirm whether the same filing covers it — the rules treat data export separately in several cases. Set one owner per workstream and one shared status sheet, and treat a red item on either side as a reason to freeze only the affected order.

Implementation checklist

  1. Map IND, ethics and HGR as three parallel tracks with separate owners.
  2. Confirm the CRO’s HGR export licence before any sample leaves a site.
  3. File a signed Chinese protocol version, not a courtesy translation.
  4. Name one decision owner, one execution owner and one review date.
  5. Keep the source page, access date, entity and internal evidence.
  6. On any change, reopen only the affected judgement.

Evidence and review

Start with the smallest test that can change the answer: Map IND, ethics and HGR as three parallel tracks with separate owners. Pick one real entity or one representative case, write down the continue, watch and stop conditions in advance, and record the input version, the owner, the start time and the actual result. The first pass should only look at facts that move the decision; formatting preferences are not risk.

The second pass is completed by “Confirm the CRO’s HGR export licence before any sample leaves a site”, and someone who did not prepare the file should spot-check one piece of critical evidence. Sponsors commonly budget for the IND clock and forget the HGR review, which can run weeks longer and sits on the critical path for any biomarker or pharmacokinetic sampling. A second frequent error is assuming a foreign-language protocol can be submitted with a courtesy translation — sites require a signed Chinese version. Exporting samples under a research-collaboration filing when the actual arrangement is a commercial one is a compliance failure, not a paperwork gap. A single small deviation can be corrected in place; a repeated deviation, or one that touches a statutory duty or changes the economics, is what justifies pausing the affected part.

After “File a signed Chinese protocol version, not a courtesy translation”, compare the actual result with the baseline rather than with the impression of the team. If the trial is China-only, file IND first and let ethics follow, because the CDE letter is the gate. If the trial feeds a global registration, build the HGR filing into the protocol timeline from the outset and contract a licensed CRO before site selection. If the sponsor intends to export data rather than samples, confirm whether the same filing covers it — the rules treat data export separately in several cases. When the arrangement is extended to more products, customers or processes, keep the same success test and one complete record per batch. If later information changes, update only the affected fields.

One last discipline keeps the file usable next quarter: write the closing note as if a colleague who has never spoken to the supplier has to act on it. That note states what was verified, on which date, against which source, and what remains open — on “Tool: A Clinical-Trial Start-Up Dossier for a Foreign Drug Sponsor in China — the NMPA IND Filing, the Ethics Committee Approval and the Human Genetic Resources Filing Behind Every Sample Export” it also states which of the three actions was actually finished and which was only scheduled. Teams that skip the closing note re-litigate the same question every month, and each round costs more than the documentation would have. General orientation for foreign sponsors, not regulatory or legal advice. NMPA and MOST practice changes; verify current requirements with CDE and the human genetic resources office before submission.

Limits of the conclusion

General orientation for foreign sponsors, not regulatory or legal advice. NMPA and MOST practice changes; verify current requirements with CDE and the human genetic resources office before submission.

The limits are structural rather than cautious wording. Public sources describe rules and market conditions; they do not observe “Tool: A Clinical-Trial Start-Up Dossier for a Foreign Drug Sponsor in China — the NMPA IND Filing, the Ethics Committee Approval and the Human Genetic Resources Filing Behind Every Sample Export” inside a specific company. Where the analysis quotes a second-hand interpretation, the original release has to remain reachable, and a figure that cannot be traced back does not enter the decision table. Where the point depends on Covers Phase I–III trials of chemical and biological drugs sponsored by a non-Chinese entity, whether conducted directly or through a Chinese affiliate. Pre-check: whether the drug is already approved in a reference market, whether the CRO holds the HGR administrative licence needed to export samples, whether the site’s ethics committee is registered, and whether any trial data will be used for a simultaneous global filing, the conclusion is only as current as the last check of those conditions.

Primary sources

Related articles

News: After Han Zheng Meets the US Second-Track Dialogue Delegation, China Deal Teams Re-Paper the Sanctions and Unreliable-Entity Representations in the SPA — What...

Information date: 21 November 2026 — On 5 June 2025 People's Daily reported that Vice Premier Han Zheng met a US high-level second-track dialogue delegation, the kind of contact that shifts deal teams' assumptions about

News: After Liu Guozhong’s Anhui Harvest Inspection, a Foreign Grain-Dryer Maker Checks Its Machine Against the Subsidy Catalogue — the MARA Promotion Certificate, the...

Information date: 21 November 2026 — On 5 June 2025 People's Daily reported that Vice Premier Liu Guozhong, during an inspection in Anhui, called for securing the summer grain harvest and laying the foundation for autumn

FAQ: Does My Plant Really Qualify for the 15% Corporate Rate — Hainan, Lingang, the Greater Bay Area and the Western Encouraged-Catalogue Route Compared...

Information date: 21 November 2026 — The 15% rate is available through several distinct routes: the Hainan Free Trade Port for encouraged-industry enterprises, the Lingang new area of the Shanghai pilot free trade zone,

Comparison: Dispatch Labour vs Post-Service Outsourcing at a China Plant — the 10% Headcount Cap, the Same-Pay Rule, the Joint-Liability Exposure and Which of...

Information date: 21 November 2026 — Dispatch labour is capped at 10% of the employer's total headcount and is confined to temporary, auxiliary or substitute positions, while post-service outsourcing is not capped but is